Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Conditions
- Atypical Ductal Breast Hyperplasia
- Lobular Carcinoma in Situ (LCIS)
- Atypical Lobular Hyperplasia (ALH) of Breast
Interventions
- DRUG: SOM 230 / Pasireotide
Sponsor
NYU Langone Health
Collaborators